AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
60.60
-1.00 (-1.62%)
Apr 17, 2026, 1:38 PM CST
Market Cap5.75B +141.5%
Revenue (ttm)7.55M -92.2%
Net Income-357.87M
EPS-3.81
Shares Out94.06M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume180,578
Average Volume313,215
Open61.20
Previous Close61.60
Day's Range60.00 - 61.50
52-Week Range17.10 - 69.90
Betan/a
RSI46.34
Earnings DateAug 12, 2026

About AnnJi Pharmaceutical

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis diseases. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7754
Full Company Profile

Financial Performance

In 2025, AnnJi Pharmaceutical's revenue was 7.55 million, a decrease of -92.17% compared to the previous year's 96.45 million. Losses were -357.87 million, 1.10% more than in 2024.

Financial Statements